Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109136 | 0.93 | MEN1 (0.39) | HDAC1HDAC2GAAUTS2R | |
| SCHEMBL462127 | 0.92 | HDAC1 (0.39) | HDAC1HDAC2SIRT1SIRT2GAA | |
| SCHEMBL1109253 | 0.89 | HDAC1 (0.53) | HDAC1HDAC2GAA | |
| SCHEMBL1109172 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2GAA | |
| SCHEMBL1109246 | 0.88 | GAA (0.55) | HDAC1HDAC2GAA | |
| SCHEMBL1109457 | 0.87 | GAA (0.41) | HDAC1HDAC2GAA | |
| SCHEMBL1109134 | 0.87 | POLB (0.43) | HDAC1HDAC2GAANAMPT | |
| SCHEMBL1109176 | 0.86 | GAA (0.45) | HDAC1HDAC2GAA | |
| SCHEMBL1109234 | 0.85 | ANPEP (0.39) | HDAC1HDAC2GAA | |
| SCHEMBL400365 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC1 824/4885HDAC2 2776/4885SIRT1 1695/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC1 824/4885HDAC2 2776/4885SIRT1 1695/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | HDAC1 824/4885HDAC2 2776/4885SIRT1 1695/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | HDAC1 824/4885HDAC2 2776/4885SIRT1 1695/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | HDAC1 824/4885HDAC2 2776/4885SIRT1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.